A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : AATD / alpha-1 antitrypsin deficiency

[Related PubMed/MEDLINE]
Total Number of Papers: 426
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   AATD  (>> Co-occurring Abbreviation)
Long Form:   alpha-1 antitrypsin deficiency
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 Alpha-1 antitrypsin deficiency and risk of lung cancer in never-smokers: a multicentre case-control study. AAT, ETS, LC
2022 Alpha-1 Antitrypsin Therapy Modifies Neutrophil Adhesion in Patients with Obstructive Lung Disease. AAT
2022 Alpha-1 Asthma Overlap Syndrome: a Clinical Overview. ---
2022 Alpha1-antitrypsin deficiency and asthma. ---
2022 Alpha1-antitrypsin deficiency and cardiovascular disease: questions and issues of a debated relation. AAT
2022 Assessing Patients with Alpha-1 Antitrypsin Deficiency for Corneal Refractive Surgery: A Review and Clinical Experience. LASIK, PRK, SMILE
2022 Attitudes Towards Vaccination for Coronavirus Disease 2019 in Patients with Severe Alpha-1 Antitrypsin Deficiency. COPD, COVID-19
2022 Augmentation therapy with human alpha-1-proteinase inhibitor reduces exacerbations in patient with bronchiectasis and alpha-1-antitrypsin deficiency. AAT, CF, COPD, NE
2022 Cancer risk in severe alpha-1-antitrypsin deficiency. ---
10  2022 Characterization of hepatic inflammatory changes in a C57BL/6J mouse model of alpha-1 antitrypsin deficiency. ---
11  2022 Cigarette smoke exposed airway epithelial cell-derived EVs promote pro-inflammatory macrophage activation in alpha-1 antitrypsin deficiency. AAT, EVs
12  2022 Comparative biochemical efficacy analysis of an alpha1-proteinase inhibitor (Glassia®) in patients with alpha-1 antitrypsin deficiency. A1PI, CIs, GMRs
13  2022 Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO. EARCO, PI
14  2022 Disease burden associated with alpha-1 antitrypsin deficiency: systematic and structured literature reviews. ---
15  2022 Disease progression in patients with PI*ZZ alpha-1 antitrypsin deficiency. ---
16  2022 Disease Status at Diagnosis in Danish Children with α 1 -antitrypsin Deficiency. GEE
17  2022 Evaluation of cytosine base editing and adenine base editing as a potential treatment for alpha-1 antitrypsin deficiency. AAT
18  2022 Ferret models of alpha-1 antitrypsin deficiency develop lung and liver disease. AAT-KO, BAL, QCT
19  2022 Frequency of alleles and genotypes associated with alpha-1 antitrypsin deficiency in clinical and general populations: Revelations about underdiagnosis. COPD
20  2022 Labelling Alpha-1 antitrypsin deficiency in the medical record - A call to action. COPD
21  2022 Long-term safety of Prolastin®-C, an alpha1-proteinase inhibitor, in Japanese patients with alpha1-antitrypsin deficiency. Alpha-1 MP, COPD, FEV1, FVC, OLE, PK, SAEs, TEAEs
22  2022 Low Prevalence of Mild Alpha-1-Antitrypsin Deficiency in Hospitalized COVID-19-Patients. AAT
23  2022 Lung Function and Health Status in Individuals with Severe Alpha-1-Antitrypsin Deficiency at the Age of 42. FOT, PFT, RV, SGRQ, TLC
24  2022 miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease. LPS
25  2022 Molecular characterization of PI * S hangzhou , a SERPINA1 allele from continental China encoding a defective alpha-1-antitrypsin. AAT
26  2022 Novel SERPINA1 Alleles Identified through a Large Alpha-1 Antitrypsin Deficiency Screening Program and Review of Known Variants. AAT
27  2022 Opinions and Attitudes of Pulmonologists About Augmentation Therapy in Patients with Alpha-1 Antitrypsin Deficiency. A Survey of the EARCO Group. AT
28  2022 Patient-Reported Pulmonary Symptoms, Exacerbations, and Management in a Cohort of Patients With Alpha-1 Antitrypsin Deficiency. ---
29  2022 Pharmacokinetics and Biochemical Efficacy of an α1-Proteinase Inhibitor (Aralast NP) in α1-Antitrypsin Deficiency: a Cross-Product Retrospective Comparability Analysis. A1PI, Aralast NP, PK
30  2022 The Clinical Course of Severe Alpha-1-Antitrypsin Deficiency in Patients Identified by Screening. COPD
31  2022 Thrombotic risk determined by rare and common SERPINA1 variants in a population-based cohort study. MAF, VTE
32  2021 A Case of Alpha-1 Antitrypsin Deficiency and Organizing Pneumonia. ---
33  2021 A Novel Detection Method to Identify Individuals with Alpha-1 Antitrypsin Deficiency: Linking Prescription of COPD Medications with the Patient-Facing Electronic Medical Record. ACT, COPD, EMR, EPM
34  2021 A rare mutation on alpha-1 antitrypsin deficit and lung fibrosis: case report. ---
35  2021 Adenine base editing reduces misfolded protein accumulation and toxicity in alpha-1 antitrypsin deficient patient iPSC-hepatocytes. ABE, iHeps, iPSCs
36  2021 Air Trapping Is Associated with Heterozygosity for Alpha-1 Antitrypsin Mutations in Patients with Asthma. AAT, PI
37  2021 Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis. AAT
38  2021 Alpha-1 Antitrypsin Augmentation Inhibits Proteolysis of Neutrophil Membrane Voltage-Gated Proton Channel-1 in Alpha-1 Deficient Individuals. ---
39  2021 Alpha-1 Antitrypsin Deficiency and Tobacco Smoking: Exploring Risk Factors and Smoking Cessation in a Registry Population. ---
40  2021 Alpha-1 antitrypsin deficiency in the elderly: a case report. AAT, AHR, COPD, FEV1
41  2021 Alpha-1 Antitrypsin Deficiency-Associated Clinical Manifestations and Healthcare Resource Use in the United States. HRU, PEs
42  2021 Alpha-1 antitrypsin deficiency-associated panniculitis. ---
43  2021 Alpha-1 antitrypsin deficiency: A re-surfacing adult liver disorder. AAT
44  2021 Alpha-1 antitrypsin deficiency: an update on clinical aspects of diagnosis and management. CT
45  2021 Alpha-1 antitrypsin deficiency: clarifying the role of the putative protective threshold. IV-AAT
46  2021 Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. COPD
47  2021 Alpha-1 Antitrypsin Z Variant (AAT PI*Z) as a Risk Factor for Intrahepatic Cholestasis of Pregnancy. ICP
48  2021 Alpha1-antitrypsin deficiency: New therapies on the horizon. AAT
49  2021 Association between circulating alpha-1 antitrypsin polymers and lung and liver disease. AAT, CP, LSM
50  2021 Association of Alpha 1-antitrypsin Deficiency and Genetic Predisposition in Primary Spontaneous Pneumothorax. PSP
51  2021 Association of alpha-1-antitrypsin deficiency with vitamin D status: who is most at risk of getting severe COVID-19? COVID-19
52  2021 Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency. ---
53  2021 Correlation between alpha1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses. AAT, SERPINA1
54  2021 COVID-19 infection in severe Alpha 1-antitrypsin deficiency: Looking for a rationale. RR
55  2021 Designing Clinical Trials in "Regular" COPD Versus Alpha-1 Antitrypsin Deficiency-Associated COPD: "More Alike Than Unalike?" COPD, FEV1
56  2021 Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. AAT, aOR
57  2021 Imaging in alpha-1 antitrypsin deficiency: a window into the disease. AAT, COPD, CT, MRI
58  2021 IntraIndividual Variability in Serum Alpha-1 Antitrypsin Levels. AAT, CI, COPD, ICC
59  2021 Investigating the Link between Alpha-1 Antitrypsin Deficiency and Abdominal Aortic Aneurysms. AAA, AAT, ECM
60  2021 Known Mutations at the Cause of Alpha-1 Antitrypsin Deficiency an Updated Overview of SERPINA1 Variation Spectrum. AAT
61  2021 Liver disease with unknown etiology - have you ruled out alpha-1 antitrypsin deficiency? AAT, LFTs
62  2021 Living with the enemy: from protein-misfolding pathologies we know, to those we want to know. AAT, T2DM
63  2021 Management of lung disease in alpha-1 antitrypsin deficiency: what we do and what we do not know. AAT
64  2021 Nephrotic syndrome secondary to alpha-1 antitrypsin deficiency. ---
65  2021 Oxidative Stress and Endoplasmic Reticulum Stress in Rare Respiratory Diseases. CF, ER, IPF, OS, PCD
66  2021 Prevalence and clinical characteristics of alpha-1 antitrypsin deficiency in liver explants in a Mexican cohort. NASH, OLT
67  2021 Prevalence of Alpha-1 Antitrypsin Deficiency, Self-Reported Behavior Change, and Health Care Engagement Among Direct-to-Consumer Recipients of a Personalized Genetic Risk Report. DTC, HCPs
68  2021 Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches. AAT, COPD, NE, PR3
69  2021 Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders. ER, ERSDs, HHHS, PD
70  2021 Relationship between alpha-1 antitrypsin deficiency and obstructive sleep apnea. ACT, BMI, KyBRFS, OSA
71  2021 Relationship between Depression and Anxiety, Health Status and Lung Function in Patients with Alpha-1 Antitrypsin Deficiency. HS
72  2021 Relationship Between α1-Antitrypsin Deficiency and Ascending Aortic Distention. ---
73  2021 Research priorities in alpha1-antitrypsin deficiency: results of a patients' and healthcare providers' international survey from the EARCO Clinical Research Collaboration. EARCO
74  2021 Severe alpha-1-antitrypsin deficiency increases the risk of venous thromboembolism. COPD, VTE
75  2021 Shear Wave Elastography and Shear Wave Dispersion Imaging in the Assessment of Liver Disease in Alpha1-Antitrypsin Deficiency. ATI, CAP, HCC, SWD, TE
76  2021 The Autophagy Pathway: A Critical Route in the Disposal of Alpha 1-Antitrypsin Aggregates That Holds Many Mysteries. AAT, UPS, Z-AAT
77  2021 The Course of AalphaVal541 as a Proteinase 3 Specific Neo-Epitope after Alpha-1-Antitrypsin Augmentation in Severe Deficient Patients. PR3
78  2021 The emerging role of proteases in alpha1-antitrypsin deficiency and beyond. ---
79  2021 The Mechanism of Mitochondrial Injury in Alpha-1 Antitrypsin Deficiency Mediated Liver Disease. ER
80  2021 The need for continuous quality assessment for providing optimal comprehensive care for patients with alpha-1 antitrypsin deficiency. EHR
81  2021 The patient perspective of alpha-1 antitrypsin deficiency: disease burden and unmet needs. ---
82  2021 The Recruitment-Secretory Block ("R-SB") Phenomenon and Endoplasmic Reticulum Storage Diseases. EM, ERSD, HHHS, R-SB
83  2021 There is No Fast Track to Identify Fast Decliners in Alpha-1 Antitrypsin Deficiency by Spirometry: A Longitudinal Study of Repeated Measurements. ---
84  2021 Treatment of alpha-1 antitrypsin deficiency using hepatic-specified cells derived from human-induced pluripotent stem cells. ELISA, HSA, iPSCs, PCR
85  2021 Understanding the genetics of chronic obstructive pulmonary disease, alpha1-antitrypsin deficiency, and implications for clinical practice. COPD
86  2021 Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil. AAT
87  2021 Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. LSM
88  2021 Variants of SERPINA1 and the increasing complexity of testing for alpha-1 antitrypsin deficiency. AAT
89  2021 [Alpha-1 antitrypsin deficiency: cause and cofactor for liver disease]. AAT
90  2021 [MDR tuberculosis, Alpha-1-anti-trypsin Deficiency, Cough in a Geriatric Nurse]. MDR-TB
91  2020 A Highly Phenotyped Open Access Repository of Alpha-1 Antitrypsin Deficiency Pluripotent Stem Cells. iPSCs
92  2020 Alpha 1-Antitrypsin Deficiency: A Disorder of Proteostasis-Mediated Protein Folding and Trafficking Pathways. CF, PN
93  2020 Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry. AAT, FEV1, RV
94  2020 Alpha-1 Antitrypsin Deficiency and Pulmonary Morbidity in Patients with Primary Immunodeficiency Disease: A Single-Center Experience. COPD, PID
95  2020 Alpha-1 antitrypsin deficiency and risk of lung cancer: A systematic review. COPD
96  2020 Alpha-1 Antitrypsin Deficiency Associated COPD. COPD
97  2020 Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients. ---
98  2020 Alpha-1 antitrypsin deficiency is under-recognized in individuals with cirrhosis undergoing liver transplantation. ---
99  2020 Alpha-1 Antitrypsin Deficiency-Mediated Liver Toxicity: Why Do Some Patients Do Poorly? What Do We Know So Far? AAT
100  2020 Alpha-1 Antitrypsin Deficiency: a Rare Disease? AAT